{"altmetric_id":4685090,"selected_quotes":["$CVM Phase 3 trial w\/est Aug completion date NCT01265849: Trial Tracker","$CVM update on clinical trail","$CVM collaborated with TEVA (USA) and ORIENT (EUROPE)","$CVM Increased sites from 68 to 73.","$CVM Phase 3 trial w\/est Dec completion date NCT01265849: Trial Tracker"],"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["CEL-SCI Corporation"],"first_seen_on":"2015-10-28T11:40:03+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1501808090,"links":["http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01265849?rank=1&term=cel-sci","http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01265849?term=multikine&rank=1","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01265849","https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01265849?term=multikine&rank=1","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01265849?term=cel-sci&rank=1","https:\/\/clinicaltrials.gov\/show\/NCT01265849"],"nct_id":"NCT01265849","pubdate":"2010-12-22T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity (IT-MATTERS)","type":"clinical_trial_study_record"},"altmetric_score":{"score":13.35,"score_history":{"1y":10,"6m":1,"3m":1,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":13.35},"context_for_score":{"all":{"total_number_of_other_articles":8320311,"mean":7.0122256031246,"rank":640334,"this_scored_higher_than_pct":92,"this_scored_higher_than":7678200,"rank_type":"exact","sample_size":8320311,"percentile":92},"similar_age_3m":{"total_number_of_other_articles":245263,"mean":9.7871141147017,"rank":26901,"this_scored_higher_than_pct":88,"this_scored_higher_than":218280,"rank_type":"exact","sample_size":245263,"percentile":88},"this_journal":{"total_number_of_other_articles":24299,"mean":10.426368507696,"rank":2258,"this_scored_higher_than_pct":90,"this_scored_higher_than":22037,"rank_type":"exact","sample_size":24299,"percentile":90},"similar_age_this_journal_3m":{"total_number_of_other_articles":1115,"mean":14.512587073609,"rank":129,"this_scored_higher_than_pct":88,"this_scored_higher_than":985,"rank_type":"exact","sample_size":1115,"percentile":88}}},"demographics":{"poster_types":{"member_of_the_public":4,"science_communicator":1},"users":{"twitter":{"cohorts":{"Members of the public":4,"Science communicators (journalists, bloggers, editors)":1}}},"geo":{"twitter":{"US":1,"CR":1}}},"counts":{"total":{"posts_count":8},"news":{"unique_users_count":1,"unique_users":["seeking_alpha"],"posts_count":2},"twitter":{"unique_users_count":5,"unique_users":["djkinwin","fda_tracker","Eternity100000","QfWallSt","naashonomics"],"posts_count":6}},"posts":{"twitter":[{"url":"https:\/\/twitter.com\/djkinwin\/status\/515833673909043200","license":"datasift","citation_ids":[4685090],"posted_on":"2014-09-27T12:01:46+00:00","author":{"name":"David Kinzel","image":"http:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_0_normal.png","id_on_source":"djkinwin","tweeter_id":"2784912060","followers":3},"tweet_id":"515833673909043200"},{"url":"http:\/\/twitter.com\/fda_tracker\/statuses\/680026398870732801","license":"gnip","citation_ids":[4685090],"posted_on":"2015-12-24T14:05:02+00:00","author":{"name":"FDA Tracker","url":"http:\/\/www.fdatracker.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1667207308\/square_logo_normal.png","description":"Analytics for Pharma and Biotech Traders","id_on_source":"fda_tracker","tweeter_id":"391492257","geo":{"lt":37.77493,"ln":-122.41942,"country":"US"},"followers":2946},"tweet_id":"680026398870732801"},{"url":"http:\/\/twitter.com\/fda_tracker\/statuses\/763360504894980097","license":"gnip","citation_ids":[4685090],"posted_on":"2016-08-10T13:05:01+00:00","author":{"name":"FDA Tracker","url":"http:\/\/www.fdatracker.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1667207308\/square_logo_normal.png","description":"Analytics for Pharma and Biotech Traders","id_on_source":"fda_tracker","tweeter_id":"391492257","geo":{"lt":37.77493,"ln":-122.41942,"country":"US"},"followers":2946},"tweet_id":"763360504894980097"},{"url":"http:\/\/twitter.com\/Eternity100000\/statuses\/763360776597811200","license":"gnip","rt":["fda_tracker"],"citation_ids":[4685090],"posted_on":"2016-08-10T13:06:06+00:00","author":{"name":"Eternity101","url":"https:\/\/twitter.com\/Eternity100000","image":"http:\/\/pbs.twimg.com\/profile_images\/459220005226160128\/M175tjCV_normal.jpeg","description":"options-volatility trader: $SPLV follower for $SPX $SPY direction","id_on_source":"Eternity100000","tweeter_id":"2363914387","geo":{"lt":null,"ln":null},"followers":1586},"tweet_id":"763360776597811200"},{"url":"http:\/\/twitter.com\/QfWallSt\/status\/446342179183525888","license":"public","citation_ids":[4685090],"posted_on":"2014-03-19T17:47:22+00:00","author":{"name":"QfWallSt","image":"http:\/\/pbs.twimg.com\/profile_images\/447378074636525569\/U6kiJzfb_normal.jpeg","description":"","id_on_source":"QfWallSt","tweeter_id":"576846469","followers":64},"tweet_id":"446342179183525888"},{"url":"http:\/\/twitter.com\/naashonomics\/statuses\/893273991590182912","license":"gnip","citation_ids":[4685090],"posted_on":"2017-08-04T00:54:50+00:00","author":{"name":"Avinash Anantharamu","url":"https:\/\/twiends.com\/naashonomics","image":"https:\/\/pbs.twimg.com\/profile_images\/775828097073418240\/05G6oFOI_normal.jpg","description":"Combining the skills of #entrepreneur, #blogger and software engineer to deliver a unique perspective on data","id_on_source":"naashonomics","tweeter_id":"881604271","geo":{"lt":9.93333,"ln":-84.08333,"country":"CR"},"followers":2056},"tweet_id":"893273991590182912"}],"news":[{"title":"A Closer Look At Cel-Sci Corporation Going Into Spring Of 2016","url":"http:\/\/ct.moreover.com\/?a=25556461893&p=1pl&v=1&x=A3tHUNwQxBy0GQkSSOKNGA","license":"public","citation_ids":[4685090],"posted_on":"2016-02-22T17:55:53+00:00","summary":"Cel-Sci Corporation (NYSEMKT: CVM ) is on the verge of several significant milestones and inflection points during the first several months of 2016.","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}},{"title":"FDA places CEL-SCI's Multikine study in head and neck cancer on clinical hold; shares off 13% premarket","url":"http:\/\/ct.moreover.com\/?a=28094644189&p=1pl&v=1&x=FvkKMaenv0GNtYY6sTDlRw","license":"public","citation_ids":[4685090],"posted_on":"2016-09-27T11:22:46+00:00","summary":"CEL-SCI Corporation (NYSEMKT: CVM ) announces that it has received verbal notice from the FDA that its Multikine (Leukocyte Interleukin Injection) Phase 3 clinical trial in advanced primary head and neck cancer has been placed on clinical hold.","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}}]}}